Trial Profile
A Multicenter, Randomized, Double-Blind Phase 3 Study Of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Previously Untreated Asian Postmenopausal Women With ER(+), HER2 (-) Advanced Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms PALOMA-4
- Sponsors Pfizer
- 03 May 2023 Planned End Date changed from 2 Dec 2022 to 31 Dec 2024.
- 22 Sep 2022 Primary results reporting efficacy and safety data in postmenopausal Asian women with ER+/HER2- advanced breast cancer published in the European Journal of Cancer
- 13 Sep 2022 Results assessing patient-reported outcomes (PROs) in Asian women presented at the 47th European Society for Medical Oncology Congress.